Rating History for Seres Therapeutics (MCRB) by Chardan

More Stocks Rated by Chardan | Latest Ratings for MCRB
Date Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
5/8/2025 Keay Nakae Downgrade Neutral
(Buy)		 6.00
(N/A)		 8.29
(7.05)		 -14.96% Details